**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 86017

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Hepatitis B virus infection in patients with Wilson disease: A large retrospective study**

Zhou HY *et al*. Concurrent HBV infection and WD

Hua-Ying Zhou, Xu Yang, Kai-Zhong Luo, Yong-Fang Jiang, Wen-Long Wang, Jun Liang, Ming-Ming Li, Hong-Yu Luo

**Hua-Ying Zhou, Xu Yang, Kai-Zhong Luo, Yong-Fang Jiang, Wen-Long Wang, Jun Liang, Ming-Ming Li, Hong-Yu Luo,** Department of Infectious Diseases, Institute of Hepatology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China

**Author contributions:** Zhou HY, Yang X, and Luo HY contributed to study conception, design and writing of the article; Yang X, Luo KZ, Jiang YF, Wang WL, Liang J, Li MM, and Luo HY contributed to data acquisition, data analysis and interpretation; Zhou HY, Yang X, and Luo HY contributed to editing, reviewing, and final approval of the article; and all authors have read and approved the final manuscript.

**Corresponding author: Hong-Yu Luo, MD, Associate Professor,** Department of Infectious Diseases, Institute of Hepatology, The Second Xiangya Hospital, Central South University, No. 139 Renming Road, Changsha 410011, Hunan Province, China. luohongyu@csu.edu.cn

**Received:** June 4, 2023

**Revised:** July 20, 2023

**Accepted:** July 31, 2023

**Published online:** August 28, 2023

**Abstract**

BACKGROUND

Wilson disease (WD) is the most common genetic metabolic liver disease. Some studies have shown that comorbidities may have important effects on WD. Data on hepatitis B virus (HBV) infection in patients with WD are limited.

AIM

To investigate the prevalence and clinical impact of HBV infection in patients with WD.

METHODS

The clinical data of patients with WD were analyzed retrospectively, and the data of patients with concurrent WD and HBV infection were compared with those of patients with isolated WD.

RESULTS

Among a total of 915 WD patients recruited, the total prevalence of current and previous HBV infection was 2.1% [95% confidence interval (CI): 1.2%-3.0%] and 9.2% (95%CI: 7.3%-11.1%), respectively. The main finding of this study was the identification of 19 patients with concurrent WD and chronic hepatitis B (CHB) infection. The diagnosis of WD was missed in all but two patients with CHB infection. The mean delay in the diagnosis of WD in patients with concurrent WD and CHB infection was 32.5 mo, which was significantly longer than that in patients with isolated WD (10.5 mo). The rates of severe liver disease and mortality in patients with concurrent WD and CHB infection were significantly higher than those in patients with isolated WD (63.1% *vs* 19.3%, *P* = 0.000 and 36.8% *vs* 4.1%, *P*< 0.001, respectively). Binary logistic regression analysis revealed a significantly higher risk of severe liver disease at the diagnosis of WD in patients with current HBV infection [odds ratio (OR) = 7.748; 95%CI: 2.890-20.774; *P* = 0.000)] or previous HBV infection (OR = 5.525; 95%CI: 3.159-8.739; *P* = 0.000) than in patients with isolated WD.

CONCLUSION

The total prevalence of current HBV infection in patients with WD was 2.1%. The diagnosis of WD in CHB patients is usually missed. HBV infection is an independent risk factor for severe liver disease in WD patients. The diagnosis of WD should be ruled out in some patients with CHB infection.

**Key Words:** Wilson disease; Hepatitis B virus; Chronic hepatitis B; Kayser-Fleischer ring; Ceruloplasmin; Concurrent Wilson disease and hepatitis B virus infection

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Zhou HY, Yang X, Luo KZ, Jiang YF, Wang WL, Liang J, Li MM, Luo HY. Hepatitis B virus infection in patients with Wilson disease: A large retrospective study. *World J Gastroenterol* 2023; 29(32): 4900-4911

**URL**: https://www.wjgnet.com/1007-9327/full/v29/i32/4900.htm

**DOI**: https://dx.doi.org/10.3748/wjg.v29.i32.4900

**Core Tip:** Data on hepatitis B virus (HBV) infection in patients with Wilson disease (WD) are limited. This is the largest investigation of HBV infection in WD patients. The most important finding of this study was the identification of 19 patients with concurrent WD and chronic hepatitis B (CHB) infection. The total prevalence of current HBV infection in patients with WD was 2.1%. The diagnosis of WD in CHB patients is usually missed. HBV infection is an independent risk factor for severe liver disease in WD patients. The diagnosis of WD should be ruled out in some patients with CHB infection.

**INTRODUCTION**

Wilson disease (WD) is an autosomal recessive disorder of copper metabolism caused by a mutation of the gene coding for copper-transporting P-type ATPase (ATP7B). It is characterized by an excessive accumulation of copper in the liver and brain, and occurs in all ethnic groups with an average prevalence of 1:30000[1,2]. The WD gene was cloned in 1993[3-5], and more than 600 gene mutations have been identified[6]. Disease progression in WD may vary, ranging from fulminant WD to an insidious progression to cirrhosis over 20-30 years. Overall, available data in literature strongly suggest that genotypic variability alone does not explain the surprisingly heterogeneous presentation of WD[7]. Some studies have shown that comorbidities may have important effects on WD[8,9].

Currently, hepatitis B virus (HBV) infection is the common cause of liver disease worldwide, affecting 290 million individuals[10,11]. However, data on the prevalence of HBV infection in WD patients are limited and inconsistent. A study from Italy reported that after monitoring 60 WD patients for 20 years, no active HBV infection was found. Accordingly, they hypothesized that the excessive copper levels caused by WD could prevent HBV infection[12]. Contrarily, a study conducted in Taiwan in 1998 reported that the prevalence of HBV infection in 61 patients with WD was 16%, which was similar to that in the general population[13]. However, this finding is different from the previously published observations of Lau *et al*[14] in Hong Kong. Moreover, these studies were conducted many years ago and in small sample size populations; therefore, more studies involving larger sample size populations are needed. Furthermore, the influence of HBV infection on the diagnosis and clinical aspect of WD remains unclear. Given the paucity of studies in this field, this study was undertaken to investigate the prevalence of HBV infection in patients with WD and to explore the impact of HBV infection on the diagnosis, clinical aspect, treatment and prognosis of WD.

**MATERIALS AND METHODS**

***Design overview, setting, and patients***

We retrospectively analyzed the data of WD patients diagnosed between May 2003 and December 2020 at the Department of Infectious Diseases/Institute of Hepatology, the Second Xiangya Hospital, Central South University, China, which is the oldest and largest tertiary referral hospital in the Hunan Province. The Institute of Hepatology of this hospital is one of the first centers to carry out research on WD in China, and it offers services to WD patients in the whole province, neighboring provinces, and all over the country.

Patients with suspected WD underwent slit-lamp examination [to identify Kayser-Fleischer (KF) rings], neurological examination, measurement of serum ceruloplasmin levels, and determination of 24 h urinary copper excretion (before and after a penicillamine challenge). In cases where there were no contraindications, a liver biopsy was performed to confirm the presence of copper deposits, and in some other cases, gene analysis was performed. The diagnosis of WD was made based on a combination of clinical symptoms and laboratory tests, and on the WD scoring system published in 2003[15,16]. WD was confirmed if the WD score was ≥ 4. The WD phenotypes were classified based on previously published criteria[16] . All WD patients were tested for HBV markers, including hepatitis B surface antigen (HBsAg), anti-HBs, hepatitis B e antigen (HBeAg), anti-HBe, and anti-HBc, at the time of diagnosis. Patients positive for HBsAg underwent further analysis to quantify HBV DNA levels. For each patient, all the data obtained at the time of diagnosis and at each follow-up time point were recorded in a medical record specifically designed for the WD study.

All the patients diagnosed with WD during the study period were eligible for inclusion. We excluded WD patients with other types of viral hepatitis (A, C, or E), autoimmune hepatitis, drug-induced liver disease, a history of alcohol intake > 30 g ethanol/day, and patients whose HBV markers were not tested.

***Laboratory methods***

Routine laboratory data were obtained using standard methods. HBV markers were tested using commercial diagnostic kits (ELISA; Shanghai Kehua Bioengineering Co. Ltd., Shanghai, China). HBV DNA levels were quantified using a commercial hepatitis B DNA quantitative fluorescence diagnostic kit (Sansure Biotech Inc, Changsha, Hunan Province, China). The lower limits of the HBV DNA quantification were 100 and 10 IU/mL before 2011 and after 2012, respectively. The KF rings were examined under a slit-lamp by an experienced ophthalmologist. Serum ceruloplasmin levels were measured using the nephelometric method (normal range, 210-500 mg/L; Beckman Coulter, Image® Immunochemistry System, Brea, CA, United States). Copper levels in serum, urine, and liver were determined as previously described[17]. Moreover, the ATP7B coding region and exon/intron boundaries were amplified and sequenced, as previously described[18].

***Study outcomes***

The study outcomes included the following: The proportion of patients with WD who had current HBV infection (positive for HBsAg); the proportion of those with previous HBV infection (negative for HBsAg but positive for anti-HBc, with or without anti-HBs); the rate of severe liver disease {defined as the proportion of WD patients who experienced severe decompensated cirrhosis [Child-Turcotte-Pugh (CTP) score ≥ 10] or acute-on-chronic liver failure (ACLF) in WD patients with HBV infection and those without HBV infection}. The CTP score was determined based on a previously described criterion[19,20]. ACLF was diagnosed according to a combination of consensus recommendations published by the Asian Pacific Association for the Study of the Liver (in 2009) and the guidelines for the diagnosis and treatment liver failure published by the Chinese Society of Hepatology in 2006[21,22]. The criteria were as follows: (1) Acute severe exacerbation of liver disease complicated within 4 wk by clinical ascites and/or encephalopathy, with previously diagnosed or undiagnosed chronic liver disease/cirrhosis; (2) Serum bilirubin ≥ 10 mg/d; and (3) Coagulopathy (international normalized ratio ≥ 1.5 or prothrombin activity < 40%).

***Statistical analysis***

Continuous data were expressed as mean ± SD and compared using the unpaired *t-*test or Mann-Whitney *U* test. Categorical variables were expressed as proportions and compared using the chi-squared test or Fishers exact test. We used a binary logistic regression model to evaluate the association between HBV infection and the risk of severe liver disease at the time of diagnosis of WD, the results were summarized as odds ratio (OR) with 95% confidence intervals (CI). All statistical analyses were performed using the software Statistical Packages for the Social sciences, SPSS version 20.0 Windows (IBM Corp., Armonk, NY, United States). Statistical significance was set at a two-tailed *P* value < 0.05.

**RESULTS**

During the study period, 973 patients were diagnosed with WD. Among them, 58 patients were excluded because of concurrent hepatitis E infection (*n* = 3), hepatitis C infection (*n* = 3), thalassemia (*n* = 3), and schistosomiasis japonica (*n* = 2), as well as insufficient length of hospital stay to perform the tests (*n* = 47). The remaining 915 patients with WD (532 men, 383 women; mean age, 20.2 ± 13.1 years; age range, 1-68 years) were included in our analysis. The patients resided in 25 provinces and belonged to 825 families. Moreover, 644 (70.4%), 218 (23.8%), 35 (3.8%), and 18 (2.0%) patients presented with only hepatic disease, neuropsychiatric and hepatic disease, only neuropsychiatric disease, and neither hepatic nor neurological disease, respectively. WD diagnosis was confirmed by a liver copper level ≥ 250 μg/g dry weight, the identification of two disease-causing mutations or homozygosity for a single disease-causing mutation, or both criteria in 320, 378, and 102 patients, respectively. All patients met the criteria of the WD scoring system, with 735 (80.3%), 87, and 93 patients having WD scores ≥ 6, 5, and 4, respectively.

***Prevalence of HBV infection among patients with WD***

Among the 915 patients with WD, 393 tested negative for all HBV markers (43.0%, 95%CI: 39.8%-46.15%) and 419 (45.8%) tested positive for immunization-related anti-HBs alone (45.8%, 95%CI: 42.5%-49.0%). The total prevalence of current and previous HBV infections were 2.1% (95%CI: 1.2%-3.0%) and 9.2% (95%CI: 7.3%-11.1%), respectively. Table 1summarizes the prevalence of HBV infection stratified by sex and age. The prevalence of both current and previous HBV infections were significantly lower in women than in men and in patients aged ≤ 10 years than in those aged ≥ 11 years. The prevalence of previous HBV infection increased with age; however, the prevalence of current HBV infection remained low irrespective of age (Table 1).

***Characteristics of WD patients with current HBV infection***

During the study period, 19 WD patients with current HBV infection were consecutively diagnosed (men, 13; women, 6; mean age, 25.1 ± 13.3 years; age range, 11-64 years). Among them, six and ten patients were positive for HBeAg and HBV DNA, respectively. Moreover, 16 patients had a 1- to 30-year history of HBV-related liver disease, among whom there were three patients who had undergone splenectomy 3 years earlier and five patients who had been receiving a treatment based on lamivudine or entecavir for 2-24 mo. All patients met the WD criteria. More specifically, WD diagnosis was based on elevated liver copper levels, identification of two disease-causing mutations or homozygosity for a single disease-causing mutation, or both in 10, 6, and 5 patients, respectively. Furthermore, 16 patients had a WD score ≥ 6 (84.2%). However, among the patients, only two were suspected of having WD; 17 were referred to our hospital because of chronic hepatitis B (CHB) and had never been diagnosed of WD before.

There was a high variability in the clinical manifestations in patients with WD and current HBV infection. Five patients (cases 2, 6, 7, 11, and 19) presented with ACLF, characterized by severe jaundice, markedly decreased albumin levels, and prolonged prothrombin time (except for case 6, the remaining four patients among these patients died within 15-30 d following diagnosis). Two and eight patients presented with evidence of compensated and decompensated cirrhosis, respectively. Two patients presented with symptoms and signs of chronic liver disease, including hepatic enlargement or abnormal serum aminotransferases levels. Two patients were entirely asymptomatic, with normal serum aminotransferase and mild hepatomegaly or splenomegaly (Tables 2-4).

***Characteristics of WD patients with previous HBV infection***

During the study period, 84 patients with WD and previous HBV infection were consecutively diagnosed (men, 52; women, 32; mean age, 33.3 ± 15.9 years; age range, 3-68 years). Among them, 74 patients were positive for anti-HBs and anti-HBc, 10 patients were positive for anti-HBc only, and none of the patients had detectable levels of HBV DNA. The diagnosis of WD was based on elevated liver copper levels, identification of two disease-causing mutations, or both in 16, 47, and 8 patients, respectively. All patients met the criteria of the WD scoring system, with 70 patients having WD scores ≥ 6 (83.3%).

***Comparison between patients with isolated WD and those with concurrent WD and HBV infection***

There were no differences in sex, WD phenotype, copper metabolism parameters (such as the positivity rates of KF rings, urinary copper excretion, and hepatic copper content), and mean WD score distribution between patients with isolated WD and those with concurrent WD and current or previous HBV infection. Compared with patients with isolated WD, WD patients having HBV infection were significantly older and had significantly more severe liver function damage (including lower serum albumin levels, higher serum total bilirubin levels, and longer prothrombin time). The ACLF rates in WD patients with current and previous HBV infection were 26.3% and 13.1%, respectively, which were significantly higher than the rate in patients with isolated WD (4.5%, *P* = 0.000). The rates of severe decompensated liver cirrhosis in WD patients with current and previous HBV infection were 40.5% and 36.8%, respectively, and these were significantly higher than the rate in patients with isolated WD (14.8%; *P* = 0.000). The mortality rates during the first 60 d of follow-up following diagnosis were 36.8% and 15.5% in WD patients with current and previous HBV infection, respectively; these values were significantly higher than the rate in patients with isolated WD (4.1%, *P* = 0.000) (Table 5). Based on the binary logistic regression analysis model, after accounting for age, sex, and HBV infection and taking as reference the groups of patients with isolated WD, there was a significantly higher risk of severe liver disease at WD diagnosis in WD patients with current (OR = 7.748; 95%CI: 2.890-20.774; *P* = 0.000) or previous HBV infection (OR = 5.525; 95%CI: 3.159-8.739; *P* = 0.000).

***Treatment and outcomes of WD patients with current HBV infection***

Five patients with concurrent WD and current HBV infection diagnosed before 2007 were treated with a chelator alone. The patients refused liver transplantation for financial reasons, rapidly deteriorated, and died from liver failure 2-4 wk after admission. Eight patients with detectable HBV DNA levels, diagnosed after 2008, were treated with a combination of penicillamine and nucleoside. Among them, two patients (cases 11 and 19) with ACLF rapidly deteriorated and died 1 mo after admission. Two patients (cases 6 and 8) were lost to follow-up. The condition of the remaining four patients gradually improved with treatment; however, one patient (case 5) developed hepatocellular carcinoma and died 7 mo after admission. Six patients with undetectable HBV DNA levels, diagnosed after 2008, were initially treated with a chelator only. Their condition gradually improved. However, three among them experienced HBV replication at 7-12 mo after therapy. Among the latter, there was one patient (case 10) with severe hepatitis reactivation and increased serum alanine aminotransferase (ALT; 930 IU/L), aspartate aminotransferase (AST; 790 IU/L), and HBV DNA (9.2 × 104 IU/mL) levels. This patient was treated with entecavir and penicillamine. However, within 2-3 mo after treatment initiation, HBV DNA levels were undetectable, and the AST and ALT levels normalized. The remaining three patients continued treatment with a chelator only. Currently, nine of the 14 patients diagnosed after 2008 have achieved a stable disease status after therapy and have resume their routine living activities (full-time work or study). WD patients with a previous HBV infection were treated using a chelator only. None of the patients experienced HBV reactivation during the study period.

**DISCUSSION**

To the best of our knowledge, the prevalence of HBV infection in patients with WD has been reported in only two small studies, and only two case studies involving single cases of concurrent WD and CHB infection have been reported in the English literature[23,24]. This is the largest investigation of HBV infection in WD patients, and it is helpful in understanding the true prevalence of HBV infection in WD patients and the impact of HBV infection on WD.

A national survey conducted in 1992 reported that the overall HBsAg prevalence in the Chinese population was 9.8%, declining to 7.2% in 2006[25,26]. In the present study, the total HBsAg prevalence was 2.1% in WD patients, a figure which is far lower than previously reported national HBsAg rates. However, this does not imply that the prevalence of HBV infection in patients with WD is lower than that in the general population. First, since the 1990s, the rate of HBV infection in China has been decreasing annually. The data of WD patients today should not be compared with those of the general population many years ago. Second, the age composition of WD patients is different from that of the general population. Among our patients, 41% were aged below 14 years; however, the HBV infection rate is known to be very low in this age group. Therefore, the average HBsAg positivity rate in WD patients should not be directly compared with that in the general population. To find studies with more comparable data, we conducted a literature search and found a large survey on HBV infection conducted in the Henan Province in 2015. This has been the largest survey on HBV infection in China during the recent years, and it involved a total of 13207 children and 16685 adults[27,28]. The Henan Province is located in the middle of China and is adjacent to Hunan. Its economic development level and HBV infection rate are similar to those in Hunan, making the data from Henan comparable with those from our study. We calculate the HBsAg positivity rates among different age groups of the WD patients, according to the age group divisions used in the Henan study (Table 6). The positivity rates of HBsAg in WD patients aged 1-4, 5-9 and 10-14 years were 0.0%, 0.0%, and 1.6%, respectively, which were similar to those in Henan children of the same age groups (0.5%, 0.7%, and 1.2%, respectively). The positivity rates of HBsAg in the 18-34, 35-54, and 55-74 years age groups of WD patients were 3.0%, 2.5%, and 5.3%, respectively, which were similar to those in the general population of the same age group (3.1%, 4.7%, and 5.1%, respectively). Our study indicates that the prevalence of HBV infection in WD patients is similar to that in the general population, and that WD patients are equally susceptible to HBV infection.

The most important finding of this study was the identification of 19 patients with concurrent WD and CHB infection. It is worth noting regarding the 19 patients that 17 were referred for CHB infection and not WD; thus, the WD was diagnosed at our hospital. There was a significant delay in the diagnosis of WD in these patients (mean delay = 32.5 and 10.5 mo in WD patients with concurrent CHB infection and in patients with isolated WD, respectively). Our results suggest that the diagnosis of WD may be missed in patients with CHB infection. Although a missed diagnosis of WD is not uncommon given the rarity of the disease[29-31], it is worth noting that many patients with CHB infection suffer from undiagnosed WD. The clinical manifestations of patients with concurrent CHB infection and WD are nonspecific and difficult to distinguish from those of patients with isolated CHB infection, unless the clinicians deliberately and diligently examine the patients to rule out WD. Therefore, more attention should be paid regarding the coexistence of WD in patients with CHB infection. WD should be considered and ruled out in some patients with CHB infection, especially in those with cirrhosis, hepatic failure, or poor response to antiviral therapies.

Compared to patients with isolated WD, patients with concurrent WD and CHB infection had significantly lower serum albumin levels, higher serum total bilirubin levels, and longer prothrombin time. The mortality rates of WD patients with current and previous HBV infection during the first 60 d of follow-up (following diagnosis) were 36.8% and 15.5%, respectively; these rates were significantly higher than those of patients with isolated WD (4.1%, *P* = 0.000). The ACLF rates in WD patients with current and previous HBV infection were 26.3% and 13.1%, respectively, which were significantly higher than those in patients with isolated WD (4.5%, *P* = 0.000). Binary logistic regression analysis revealed that the risk of severe liver disease in WD patients with current and previous HBV infection was 7.7 and 5.3 times (respectively) higher than that in patients with isolated WD. Our findings indicate that HBV infection substantially affects the severity liver disease in patients with WD (Tables 5 and 7). The mechanism through which CHB causes severe liver injury could involve the induction, by viral hepatitis, of hepatic injury and copper accumulation, which could additively or synergistically aggravate WD-induced liver damage. Many studies have shown that HBsAg clearance usually results in good long-term prognosis[32]. However, an unexpected finding was that previous HBV infection also had a significant impact on the severity of liver disease in patients with WD. The reason for this may be that WD patients with a previous HBV infection usually have severe liver injury and cirrhosis (due to the joint action of HBV and WD) that occurred before the HBsAg clearance. After the HBsAg clearance, the severe liver injury and cirrhosis that had been formed usually persist[33,34]. Considering the serious impact of HBV infection on the clinical aspect of WD patients, current and previous HBV infections must be screened when evaluating the clinical aspect and prognosis of WD patients.

The strengths of this study are: (1) Considering the rarity of the disease, the sample size of the WD patient cohort was very large; (2) All patients were diagnosed in our department and met the diagnostic criteria; among them, 80% were confirmed by genetic examination and/or liver copper level determination; and (3) All data were prospectively collected by the authors and therefore were complete and reliable. The limitation of this study is the relatively small number of WD patients with concurrent CHB infection, as this might impede the detection of more significant differences between patients with isolated WD and those with co-existing CHB infection and WD.

In conclusion, our study indicates that the prevalence of HBV infection stratified by sex and age in patients with WD is similar to that in the general population. There was a significant delay in the diagnosis of WD in CHB patients. Furthermore, our findings suggest that HBV infection significantly affects the severity of liver disease in patients with WD. Therefore, more attention should be paid to patients suffering from concurrent WD and CHB infection. Although we found that previous HBV infection is an independent factor in the exacerbation of WD, its mechanism remains unknown. Further research is needed to confirm this finding and to elucidate the mechanisms underlying the associations between WD progression and previous HBV infection or cryptogenic HBV infection.

**CONCLUSION**

This is the largest investigation of HBV infection in WD patients, and it is helpful in understanding the true prevalence of HBV infection in WD patients and the impact of HBV infection on WD.

**ARTICLE HIGHLIGHTS**

***Research background***

Although hepatitis B virus (HBV) infection is the most common cause of liver disease in China, the occurrence of HBV infection in Wilson disease (WD) patients and the clinical manifestations of concurrent WD and HBV infections have rarely been reported.

***Research motivation***

Our study suggests that both WD and HBV infections may coexist. The clinical symptoms of concurrent WD and HBV infections are difficult to distinguish from those of simple viral hepatitis. Therefore, the existence of WD may be hidden. The study of concurrent WD and HBV infection deserves careful consideration.

***Research objectives***

To investigate the incidence of HBV infection in patients with WD and to analyse how HBV infection affects WD.

***Research methods***

The clinical data of patients with WD were analyzed retrospectively, and the data of patients with concurrent WD and HBV infection were compared with those of patients with isolated WD. Considering the rarity of the disease, the sample size of the WD patient cohort was very large.

***Research results***

Among a total of 915 WD patients recruited, the total prevalence of current and previous HBV infection was 2.1% and 9.2% respectively. The main finding of this study was the identification of 19 patients with concurrent WD and chronic hepatitis B (CHB) infection. The mean delay in the diagnosis of WD in patients with concurrent WD and CHB infection was 32.5 mo, which was significantly longer than that in patients with isolated WD (10.5 mo). The rates of severe liver disease and mortality in patients with concurrent WD and CHB infection were significantly higher than those in patients with isolated WD (63.1% *vs* 19.3%), respectively. Binary logistic regression analysis revealed a significantly higher risk of severe liver disease at the diagnosis of WD in patients with current HBV infection or previous HBV infection than in patients with isolated WD.

***Research conclusions***

Our study indicates that the prevalence of HBV infection stratified by sex and age in patients with WD is similar to that in the general population. There was a significant delay in the diagnosis of WD in CHB patients. HBV infection is an independent risk factor for severe liver disease in WD patients. WD should be considered and excluded in some patients with CHB infection.

***Research perspectives***

As we found that previous HBV infection was an independent factor in the exacerbation of WD, the mechanism of which is speculative, future studies could further explore the mechanism by which WD is exacerbated by previous HBV infection and whether it is related to occult HBV infection.

**REFERENCES**

1 **Walshe JM**. History of Wilson's disease: 1912 to 2000. *Mov Disord* 2006; **21**: 142-147 [PMID: 16229009 DOI: 10.1002/mds.20694]

2 **Frydman M**. Genetic aspects of Wilson's disease. *J Gastroenterol Hepatol* 1990; **5**: 483-490 [PMID: 2129820 DOI: 10.1111/j.1440-1746.1990.tb01427.x]

3 **Bull PC**, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. *Nat Genet* 1993; **5**: 327-337 [PMID: 8298639 DOI: 10.1038/ng1293-327]

4 **Tanzi RE**, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, Romano DM, Parano E, Pavone L, Brzustowicz LM. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. *Nat Genet* 1993; **5**: 344-350 [PMID: 8298641 DOI: 10.1038/ng1293-344]

5 **Yamaguchi Y**, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. *Biochem Biophys Res Commun* 1993; **197**: 271-277 [PMID: 8250934 DOI: 10.1006/bbrc.1993.2471]

6 **Gao J**, Brackley S, Mann JP. The global prevalence of Wilson disease from next-generation sequencing data. *Genet Med* 2019; **21**: 1155-1163 [PMID: 30254379 DOI: 10.1038/s41436-018-0309-9]

7 **Ferenci P**, Stremmel W, Członkowska A, Szalay F, Viveiros A, Stättermayer AF, Bruha R, Houwen R, Pop TL, Stauber R, Gschwantler M, Pfeiffenberger J, Yurdaydin C, Aigner E, Steindl-Munda P, Dienes HP, Zoller H, Weiss KH. Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease. *Hepatology* 2019; **69**: 1464-1476 [PMID: 30232804 DOI: 10.1002/hep.30280]

8 **Sallie R**, Chiyende J, Tan KC, Bradley D, Portmann B, Williams R, Mowat AP, Mieli-Vergani G. Fulminant hepatic failure resulting from coexistent Wilson's disease and hepatitis E. *Gut* 1994; **35**: 849-853 [PMID: 8020819 DOI: 10.1136/gut.35.6.849]

9 **Wong RJ**, Gish R, Schilsky M, Frenette C. A clinical assessment of Wilson disease in patients with concurrent liver disease. *J Clin Gastroenterol* 2011; **45**: 267-273 [PMID: 20535024 DOI: 10.1097/MCG.0b013e3181dffaa5]

10 **Chien RN**, Liaw YF. Current Trend in Antiviral Therapy for Chronic Hepatitis B. *Viruses* 2022; **14** [PMID: 35216027 DOI: 10.3390/v14020434]

11 **Polaris Observatory Collaborators**. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol* 2018; **3**: 383-403 [PMID: 29599078 DOI: 10.1016/S2468-1253(18)30056-6]

12 **Liggi M**, Sini M, Sorbello O, Civolani A, Demelia L. HBV and HCV infections in Wilson's disease patients: copper overload could be protective? *Clin Biochem* 2012; **45**: 1095-1096 [PMID: 22569595 DOI: 10.1016/j.clinbiochem.2012.04.026]

13 **Yu JM**, Chu EC, Chu NC, Huang CC. Wilsons disease with hepatitis B infection: occurrence, clinical presentation, and prognosis. *Acta Neurol Taiwan* 1998; **7**: 262-265

14 **Lau JY**, Lai CL, Wu PC, Pan HY, Lin HJ, Todd D. Wilson's disease: 35 years' experience. *Q J Med* 1990; **75**: 597-605 [PMID: 2217665]

15 **Roberts EA**, Schilsky ML; American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. *Hepatology* 2008; **47**: 2089-2111 [PMID: 18506894 DOI: 10.1002/hep.22261]

16 **Ferenci P**, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, Schilsky M, Cox D, Berr F. Diagnosis and phenotypic classification of Wilson disease. *Liver Int* 2003; **23**: 139-142 [PMID: 12955875 DOI: 10.1034/j.1600-0676.2003.00824.x]

17 **Yang X**, Tang XP, Zhang YH, Luo KZ, Jiang YF, Luo HY, Lei JH, Wang WL, Li MM, Chen HC, Deng SL, Lai LY, Liang J, Zhang M, Tian Y, Xu Y. Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample. *Hepatology* 2015; **62**: 1731-1741 [PMID: 26095812 DOI: 10.1002/hep.27932]

18 **Coffey AJ**, Durkie M, Hague S, McLay K, Emmerson J, Lo C, Klaffke S, Joyce CJ, Dhawan A, Hadzic N, Mieli-Vergani G, Kirk R, Elizabeth Allen K, Nicholl D, Wong S, Griffiths W, Smithson S, Giffin N, Taha A, Connolly S, Gillett GT, Tanner S, Bonham J, Sharrack B, Palotie A, Rattray M, Dalton A, Bandmann O. A genetic study of Wilson's disease in the United Kingdom. *Brain* 2013; **136**: 1476-1487 [PMID: 23518715 DOI: 10.1093/brain/awt035]

19 **Child CG**, Turcotte JG. Surgery and portal hypertension. In: Child CG. The liver and portal hypertension. Philadelphia: Saunders, 1964: 50-64

20 **Pugh RN**, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973; **60**: 646-649 [PMID: 4541913 DOI: 10.1002/bjs.1800600817]

21 **Sarin SK**, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). *Hepatol Int* 2009; **3**: 269-282 [PMID: 19669378 DOI: 10.1007/s12072-008-9106-x]

22 **Liver Failure and Artificial Liver Group**, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. [Diagnostic and treatment guidelines for liver failure]. *Zhonghua Gan Zang Bing Za Zhi* 2006; **14**: 643-646 [PMID: 16995974]

23 **Seto WK**, Mak CM, But D, Hung I, Lam CW, Tam S, Yuen MF, Lai CL. Mutational analysis for Wilson's disease. *Lancet* 2009; **374**: 662 [PMID: 19700008 DOI: 10.1016/S0140-6736(09)60915-6]

24 **Lopez Morra HA**, Debes JD, Dickstein G. Wilson's disease: what lies beneath. *Dig Dis Sci* 2007; **52**: 941-942 [PMID: 17333351 DOI: 10.1007/s10620-006-9463-z]

25 **Liang X**, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. *Vaccine* 2009; **27**: 6550-6557 [PMID: 19729084 DOI: 10.1016/j.vaccine.2009.08.048]

26 **Lu FM**, Li T, Liu S, Zhuang H. Epidemiology and prevention of hepatitis B virus infection in China. *J Viral Hepat* 2010; **17** Suppl 1: 4-9 [PMID: 20586928 DOI: 10.1111/j.1365-2893.2010.01266.x]

27 **Yonghao G**, Jin X, Jun L, Pumei D, Ying Y, Xiuhong F, Yanyang Z, Wanshen G. An epidemiological serosurvey of hepatitis B virus shows evidence of declining prevalence due to hepatitis B vaccination in central China. *Int J Infect Dis* 2015; **40**: 75-80 [PMID: 26456567 DOI: 10.1016/j.ijid.2015.10.002]

28 **Yong Hao G**, Da Xing F, Jin X, Xiu Hong F, Pu Mei D, Jun L, Ying Y, Yan Yang Z, Wan Shen G. The prevalence of hepatitis B infection in central China: An adult population-based serological survey of a large sample size. *J Med Virol* 2017; **89**: 450-457 [PMID: 27504586 DOI: 10.1002/jmv.24649]

29 **Walshe JM**, Yealland M. Wilson's disease: the problem of delayed diagnosis. *J Neurol Neurosurg Psychiatry* 1992; **55**: 692-696 [PMID: 1527540 DOI: 10.1136/jnnp.55.8.692]

30 **Brewer JG**. Wilsons disease: a clinician guide to recognition, diagnosis, and management. 1st ed. Amsterdam: Kluwer Academic Publishers, 2001

31 **Hu J**, Lü D, Wang G. [Study on the clinical misdiagnosis of hepatolenticular degeneration]. *Zhonghua Yi Xue Za Zhi* 2001; **81**: 642-644 [PMID: 11798938]

32 **Yuen MF**, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. *Hepatology* 2004; **39**: 1694-1701 [PMID: 15185311 DOI: 10.1002/hep.20240]

33 **Wang H**, Swann R, Thomas E, Innes HA, Valerio H, Hayes PC, Allen S, Barclay ST, Wilks D, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley AJ, Gunson R, Mclntyre PG, Hunt A, Hutchinson SJ, Mills PR, Dillon JF. Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis. *J Viral Hepat* 2018; **25**: 930-938 [PMID: 29577515 DOI: 10.1111/jvh.12897]

34 **D'Amico G**, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol* 2006; **44**: 217-231 [PMID: 16298014 DOI: 10.1016/j.jhep.2005.10.013]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Ethical Committee of the Second Xiangya Hospital of Central South University, (2022) Lun Shen [Lin Yan] No. (194).

**Informed consent statement:** Informed consent was waived by the Ethical Committee of the Second Xiangya Hospital of Central South University.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** The original anonymous dataset is available on request from the corresponding author luohongyu@csu.edu.cn.

**STROBE statement:** The authors have read the STROBE Statement checklist of items, and the manuscript was prepared according to the STROBE statement checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 4, 2023

**First decision:** July 8, 2023

**Article in press:** July 31, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Elpek GO, Turkey; Shahid M, Pakistan **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Chen YX

**Table 1 Prevalence of hepatitis B infection in patients with Wilson disease stratified by gender and age**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Number of patients** | **Negative for HBVM (%)** | **Anti-HBs(+) alone (%)** | **Prior HBV infection (%)** | **Current HBV infection (%)** |
| **Total group** | 915 | 393 (43.0) | 419 (45.8) | 84 (9.2) | 19 (2.1) |
| **Sex** |  |  |  |  |  |
| Male | 532 | 228 (42.9) | 239 (44.9) | 52 (9.8) | 13 (2.4) |
| Female | 383 | 165 (43.1) | 180 (47.0) | 32 (8.4) | 6 (1.6) |
| **Age group (yr)** |  |  |  |  |  |
| 2-10 | 231 | 105 (45.5) | 119 (51.5) | 7 (3.0) | 0 (0.0) |
| 11-20 | 340 | 156 (45.9) | 159 (46.8) | 15 (4.4) | 10 (2.9) |
| 21-30 | 153 | 63 (41.2) | 73 (47.7) | 13 (8.5) | 4 (2.6) |
| 31-40 | 106 | 40 (37.7) | 42 (39.6) | 21 (19.8) | 3 (2.8) |
| 41-65 | 85 | 29 (34.1) | 26 (30.6) | 28 (32.9) | 2 (2.3) |

HBVM: Hepatitis B virus markers; HBV: Hepatitis B virus.

**Table 2 Characteristics of patients with Wilson disease and chronic hepatitis B: The demographic characteristics and parameters of hepatitis B virus infection**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Case** | **Sex** | **Age (yr)** | **History of****HBV (yr)** | **HBsAg** | **HBeAg** | **Anti-HBe** | **HBV DNA** |
| 1 | Female | 16 | 2 | + | - | + | < 100 |
| 2 | Male | 19 | 2 | + | - | + | 9.3e8 |
| 3 | Female | 19 | 2 | + | - | - | < 100 |
| 4 | Male | 26 | 3 | + | + | - | 1.9e6 |
| 5 | Male | 43 | 3 | + | - | + | 5.6e5 |
| 6 | Female | 37 | 2 | + |  | + | 7.3e3 |
| 7 | Male | 19 | 3 | + | - | + | < 100 |
| 8 | Male | 11 | 5 | + | + | - | 3.2e7 |
| 9 | Male | 26 | 20 | + | - | + | 1.9e4 |
| 10 | Female | 17 | 3 | + | - | + | < 10 |
| 11 | Male | 20 | 10 | + | + | - | 2.3e4 |
| 12 | Male | 11 | ? | + | - | + | < 10 |
| 13 | Female | 32 | ? | + | - | + | 81 |
| 14 | Male | 27 | ? | + | + | - | 1.3e6 |
| 15 | Male | 24 | 16 | + | + | - | 2.1e8 |
| 16 | Male | 15 | 16 | + | - | + | < 10 |
| 17 | Male | 65 | 30 | + | - | + | 22.3 |
| 18 | Female | 35 | 16 | + | - | + | < 10 |
| 19 | Male | 15 | 10 | + | + | - | 1.8e6 |

HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen.

**Table 3 Characteristics of patients with Wilson disease and chronic hepatitis B: Diagnostic parameters of Wilson disease**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Case** | **Neurologic signs** | **KF rings** | **Cerulo plasmin (mg/L)** | **Urinary copper/after PC (μg/24 h)** | **Hepatic copper (μg/g/dw)** | **Mutation analysis** | **WD score** |
| 1 | No | P | 65.0 | 177/1600 | ND | ND | 5 |
| 2 | No | P | 50.0 | 1222/4250 | ND | ND | 6 |
| 3 | No | P | 95.0 | 1818/2266 | ND | ND | 6 |
| 4 | Yes | P | 187.0 | 434/Nd | ND | ND | 7 |
| 5 | No | P | 172.0 | 107/1295 | 347 | ND | 6 |
| 6 | No | P | 216.0 | 431/1436 | 1165 | ND | 6 |
| 7 | No | P | 50.0 | 5171/15398 | ND | ND | 6 |
| 8 | No | P | 250.0 | 305/1933 | 1173 | ND | 6 |
| 9 | No | N | 74.0 | 474/1500 | 926 | 3532G>T/3532G>T | 10 |
| 10 | No | P | 84.0 | 595/1725 | ND | 2755C>G/2975C>T | 10 |
| 11 | No | N | 135.0 | 1297/2984 | ND | 588C>A/2333G>T | 7 |
| 12 | No | P | 78.4 | 160/1773 | 741 | 2975C>T/2975C>T | 11 |
| 13 | No | P | 129 | 855/2505 | ND | ND | 5 |
| 14 | No | P | 31.0 | 310/1984 | 1067 | 3809 >G/ | 9 |
| 15 | No | N | 104.0 | 187/1836 | 896 | 0 | 4 |
| 16 | Yes | P | 86.5 | 237/2374 | 404 | ND | 10 |
| 17 | No | P | 83.1 | 64/714 | 265 | 2975C>T/ | 7 |
| 18 | No | P | 43.0 | 155/171 | 906 | 2804C>T/2810delT | 11 |
| 19 | No | P | 63.0 | 584/2473 | ND | 2666G>T/2333G>T | 10 |

WD: Wilson disease; KF rings: Kayser-Fleischer rings; ND: Not done; PC: Penicillamine challenge; N: Negative; P: Positive.

**Table 4 Characteristics of patients with Wilson disease and chronic hepatitis B: Parameters of liver disease**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case** | **ALT** | **AST** | **ALB** | **TBIL** | **GGT** | **ALP** | **INR** | **Severity of liver disease** | **Outcome** |
| 1 | 29 | 50 | 20.3 | 46.7 | 46 | 74 | 2.61 | CTP: 13 | Died |
| 2 | 70 | 185 | 26.8 | 264 | 84 | 61 | 2.8 | ACLF | Died |
| 3 | 86 | 50 | 25.1 | 123 | 58 | 85 | 2.7 | CTP: 13 | Died |
| 4 | 41 | 60 | 30.4 | 44.4 | 90 | 70 | 4.5 | CTP: 13 | Died |
| 5 | 102 | 170 | 35.7 | 48.0 | 110 | 95 | 1.5 | CTP: 10 | Died |
| 6 | 119 | 291 | 27.6 | 417 | 186 | 390 | 2.1 | ACLF | Alive |
| 7 | 79 | 123 | 31 | 456 | 45 | 57 | 4.1 | ACLF | Died |
| 8 | 231 | 237 | 37.5 | 16.5 | 353 | 105 | 1.2 | CTP:6 | Alive. |
| 9 | 74 | 101 | 29.8 | 39.0 | 42 | 116 | 1.5 | CTP:10 | Alive |
| 10 | 79 | 105 | 24.5 | 42.0 | 110 | 130 | 2.4 | CTP:12 | Alive |
| 11 | 223 | 268 | 30.0 | 368 | 147 | 252 | 2.8 | ACLF | Died |
| 12 | 71 | 83 | 31.0 | 23.0 | 62 | 357 | 1.6 | CTP:10 | Alive |
| 13 | 70 | 76 | 28.0 | 25.6 | 35 | 375 | 1.63 | CTP:10 | Alive |
| 14 | 82 | 151 | 37.8 | 28.7 | 152 | 149 | 1.36 | CTP:5 | Alive |
| 15 | 276 | 102 | 39.9 | 25.3 | 113 | 93 | 0.95 | Hepatitis | Alive |
| 16 | 22 | 47 | 36.5 | 16 | 32 | 219 | 1.25 | Hepatitis | Alive |
| 17 | 31 | 28 | 47.3 | 26.3 | 23 | 76 | 1.01 | Hepatitis | Alive |
| 18 | 56 | 34 | 42.0 | 22.0 | 90 | 60 | 1.01 | Hepatitis | Alive |
| 19 | 57 | 74 | 28.0 | 373 | 268 | 293 | 3.01 | ACLF | Died |

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALB: Albumin; TBIL: Total bilirubin; GGT: Gamma-glutamyl transpeptidase; ALP: Alkaline phosphatase; INR: International normalized ratio; ACLF: Acute-on-chronic liver failure; CTP: Child-Turcotte-Pugh.

**Table 5 Factors associated with severe liver disease at the Wilson disease diagnosis**

|  |  |  |  |
| --- | --- | --- | --- |
| **Factors (at diagnosis)** | **OR** | **95%CI** | ***P* value** |
| Gender |  |  |  |
| Male | 1 |  |  |
| Female | 1. 945 | 1.402-2.698 | 0.000 |
| Age at diagnosis (yr) |  |  |  |
| Group 1 (0-10) | 1 |  |  |
| Group 2 (11-20) | 1.766 | 1.145-2.723 | 0.010 |
| Group 3 (21-30) | 0.757 | 0.423-1.352 | 0.346 |
| Group 4 (31-40) | 1.178 | 0.646-2.148 | 0.594 |
| Group 5 (41-65) | 1.455 | 0.777-2.724 | 0.241 |
| HBV infection |  |  |  |
| WD alone | 1 |  |  |
| WD with previous HBV | 5.255 | 3.159-8.739 | 0.000 |
| WD with current HBV | 7.748 | 2.890-20.774 | 0.000 |

Severe liver disease is defined as patients with acute-on-chronic liver failure or a Child-Turcotte-Pugh score ≥ 10 at the Wilson disease diagnosis, HBV: Hepatitis B virus; WD: Wilson disease; OR: Odds ratio; CI: Confidence interval.

**Table 6 Comparison of hepatitis B surface antigen positivity rates among different age groups between patients with Wilson disease and the general population**

|  |  |  |  |
| --- | --- | --- | --- |
| **Age groups (yr)** | **Wilson disease** | **General population (Henan)** | ***P* value** |
| **Number tested** | **HBsAg(+) (*n*, %)** | **Number tested** | **HBsAg(+) (*n*, %)** |
| 1-4 | 40 | 0, 0.0 | 5474 | 26, 0.5 | 0.827 |
| 5-9 | 148 | 0, 0.0 | 4407 | 32, 0.7 | 0.625 |
| 10-14 | 191 | 3, 1.6 | 3376 | 40, 1.2 | 0.505 |
| 15-17 | 97 | 3, 3.1 | Not done |  |  |
| 18-34 | 298 | 9, 3.0 | 6764 | 220, 3.1 | 0.825 |
| 35-54 | 122 | 3, 2.5 | 6777 | 275, 4.7 | 0.490 |
| 55-74 | 19 | 1, 5.3 | 3144 | 147, 5.1 | 0.599 |
| Total | 915 | 19, 2.1 | 29892 | 740, 2.5 | 0.510 |

HBsAg: Hepatitis B surface antigen.

**Table 7 Comparison between Wilson disease patients alone and Wilson disease patients with hepatitis B virus infection**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **WD alone (*n* = 812)** | **With previous HBV (*n* = 84)** | **With current HBV (*n* = 19)** | **P1** | **P2** |
| **Sex** |  |  |  |  |  |
| Male (*n*, %) | 467 (57.5) | 46 (61.9) | 12 (63.2) | 0.509 | 0.797 |
| Female (*n*, %) | 345 (42.5) | 32 (38.1) | 7 (36.8) | 0.509 | 0.797 |
| Mean age (yr) | 18.8 ± 12.0 | 33. ± 15.9 | 25.0 ± 13. | 0.000 | 0.031 |
| Diagnosis delay | 12.1 ± 21.3 | 13.7 ± 26.1 | 34.6 ± 53.5 | 0.542 | 0.000 |
| **Phenotype** |  |  |  |  |  |
| Pure H (*n*, %) | 564 (69.5) | 63 (75.0) | 17 (89.5) | 0.352 | 0.104 |
| H and N (*n*, %) | 195 (24.40) | 21 (25.60) | 2 (10.5) | 0.352 | 0.104 |
| Pure N (*n*, %) | 35 (4.3) | 0 (0.0) | 0 |  |  |
| Others (*n*, %) | 18 (2.2) | 0 | 0 |  |  |
| **Copper metabolic** |  |  |  |  |  |
| KF positive | 67.6% | 84.1% | 78.9% | 0.102 | 0.456 |
| Ceruloplasmin | 64.1 ± 46.0 | 97.1 ± 60.3 | 105.0 ± 61.6 | 0.000 | 0.000 |
| Urinary copper | 502.4 ± 1030.5 | 916.3 ± 245.8 | 767.7 ± 1165.0 | 0.005 | 0.323 |
| Urinary Cu after PC | 2236.4 ± 1582.1 | 2283.7 ± 1287.8 | 2793.8 ± 3157.5 | 0.842 | 0.144 |
| Hepatic Cu | 832.2 ± 457.7 | 680.1 ± 407.7 | 789.0 ± 338.2 | 0.191 | 0.767 |
| Mean WD score | 7.4 ± 2.3 | 8.0 ± 2.2 | 7.8 ± 2.3 | 0.124 | 0.412 |
| **Biochemical** |  |  |  |  |  |
| ALT (IU/L) | 86.2 ± 105.7 | 63.3 ± 51.0 | 94.6 ± 71.1 | 0.0051 | 0.722 |
| AST (IU/L) | 84.25 ± 90.3 | 90.47 ± 70.4 | 125.3 ± 80.5 | 0.0532 | 0.058 |
| Albumin (g/L) | 38.5 ± 8.3 | 32.5 ± 7.6 | 32.1 ± 6.8 | 0.000 | 0.001 |
| TBIL (μmol/L) | 52.1 ± 131.0 | 104.7 ± 166.7 | 126.6 ± 158.3 | 0.001 | 0.002 |
| GGT (IU/L) | 90.9 ± 85.6 | 138.6 ± 112.3 | 109 ± 93.3 | 0000 | 0.399 |
| ALP (IU/L) | 186.7 ± 133.6 | 137.7 ± 87.7 | 171.9 ± 123.0 | 0.001 | 0.650 |
| INR | 1.42 ± 0.81 | 1.88 ± 0.86 | 2.09 ± 1.04 | 0.000 | 0.000 |
| **Liver disease severity** |  |  |  |  |  |
| Hepatitis (*n*, %) | 372 (45.8) | 7 (8.3) | 3 (15.8) | 0.000 | 0.009 |
| CTP5-6 (*n*, %) | 189 (23.3) | 18 (21.4) | 3 (15.8) | 0.702 | 0.444 |
| CTP7-9 (*n*, %) | 94 (11.6) | 14 (16.7) | 1 (5.3) | 0.173 | 0.713 |
| CTP10-14 (*n*, %) | 120 (14.8) | 34 (40.5) | 7 (36.8) | 0.000 | 0.008 |
| ACLF (*n*, %) | 37 (4.5) | 11 (13.1) | 5 (26.3) | 0.001 | 0.000 |
| Mortality (*n*, %), | 33 (4.1) | 13 (15.5) | 7 (36.8) | 0.000 | 0.000 |

HBV: Hepatitis B virus; WD: Wilson disease; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; GGT: Gamma-glutamyl transpeptidase; ALP: Alkaline phosphatase; INR: International normalized ratio; ACLF: Acute-on-chronic liver failure; CTP: Child-Turcotte-Pugh; PC: Penicillamine challenge.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**